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A 28-year-old never-smoking man presented with 6 months of gradually worsening low back pain, weight loss, and 
leg weakness. Computed tomography scans in January 2009 
showed a 1.4 × 2.3 cm spiculated left lower-lobe mass with 
adjacent subcentimeter nodules, multiple areas of adenopathy, 
bony lesions in the lower spine and pelvis, and liver lesions. 
A magnetic resonance imaging of the brain on February 3, 
2009 demonstrated multiple, small, enhancing lesions con-
sistent with metastatic disease, the largest of which was 
1.7 × 1.6 × 1.6 cm in the left occipital lobe.
A biopsy of a left supraclavicular lymph node on 
February 2, 2009 demonstrated metastatic poorly differenti-
ated lung adenocarcinoma. Genetic testing demonstrated an 
EML4-ALK translocation.
The patient underwent a course of whole-brain radia-
tion concurrently with radiation to the lumbar spine, finishing 
on March 3, 2009. After completion of whole-brain radiation, 
he underwent stereotactic boost to four lesions on March 17, 
2009. Thereafter, he was enrolled to a phase I trial (A8081001) 
of crizotinib (Xalkori; Pfizer, New York, NY) at a dose of 
250 mg twice daily on April 1, 2009 and had a partial response 
to this therapy. During his course on study (close to 3 years), he 
underwent stereotactic radiosurgery to additional new central 
nervous system (CNS) lesions in May and August 2011.
In January 2012, routine restaging computed tomogra-
phy showed overall stable systemic disease other than growth 
in an isolated right paratracheal node. However, brain mag-
netic resonance imaging showed the new development of 
more than 30 small lesions throughout the cerebrum and cer-
ebellum in addition to increase in pre-existing lesions.
At this juncture, we initiated therapy with high-dose 
pemetrexed (900 mg/m2) (Alimta; Lilly, Indianapolis, IN) in 
combination with the highest tested dose of crizotinib without 
dose-limiting toxicity as of January 2012 (600 mg once daily) 
with the rationale of giving the highest doses that could be 
safely administered of both agents to maximize potential cere-
brospinal fluid penetration.
Scans performed 6 weeks after initiation of this ther-
apy demonstrated reduction in multiple CNS lesions (Fig. 1). 
The growing right paratracheal node also regressed on ther-
apy (Fig. 2). In addition, lesions that were previously stable 
on crizotinib showed further decrease on being treated with 
this combination (Fig. 3), suggesting additive or synergistic 
effects. The patient continues to have minimal adverse effects 
and overall stable cerebral and systemic disease 7 months 
after initiation of therapy.
DISCUSSION
Pemetrexed has previously been identified to have activ-
ity in CNS metastases in non–small-cell lung cancer1 and 
some studies (but not all) have suggested ALK rearrange-
ments are associated with durable responses to pemetrexed.2–4 
This patient had not previously received chemotherapy and 
pemetrexed alone may have given a similar result. However, 
because at the time of initation of therapy, the patient remained 
asymptomatic with largely stable disease, we felt that he was 
still receiving clinical benefit from crizotinib and that CNS 
growth likely represented the inadequate CNS penetration of 
crizotinib.5 Although now Food and Drug Administration–
approved,6 dose escalation is still ongoing in the A8081001 
phase I study of crizotinib. Therefore, on the basis of nonover-
lapping toxicities, we used high-dose crizotinib in combina-
tion with high-dose pemetrexed, which has shown equivalent 
systemic safety and efficacy in non–small-cell lung cancer7 
and promising activity in CNS lymphoma.8 Although we do 
not know whether the response seen here was attributable to 
one or both drugs given at high dose, the minimal toxicity and 
sustained clinical benefit seen here suggest the combination is 
worthy of further exploration.
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FIGURE 1.  Central nervous system metas-
tases showing regression on combination 
pemetrexed + crizotinib therapy. A and C, 
T1 postgadolinium images from a scan on 
January 3, 2012, before the initiation of 
therapy. B and D, similar images from a scan 
on February 27, 2012, 6 weeks after the 
initiation therapy. 
FIGURE 2.  Regression of growing lesion 
of combination pemetrexed + crizotinib 
therapy. A, A high right paratracheal node as 
imaged on October 14, 2011, in the setting 
of systemic stable disease (after 2.8 years on 
phase I trial of crizotinib at 250 mg orally 
twice daily. B, The same node on January 3, 
2012, at the time of central nervous system 
progression. C, The same node on February 
27, 2012, after 6 weeks of therapy.
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FIGURE 3.  Regression of previously stable 
lesion on combination pemetrexed + crizo-
tinib therapy. A, Right subcarinal node at 
the time of entry onto study with crizotinib 
(250 mg twice daily) on March 27, 2009. 
B, The same node in the setting of systemic 
stable disease after 2.8 years on therapy 
(October 14, 2011). C, The node at the time 
of central nervous system progression on 
January 3, 2012 (still stable). D, The node on 
February 27, 2012 after 6 weeks on therapy.
